NanoViricides Inc., a publicly traded company specializing in the development of broad-spectrum antivirals, has announced the progression of its lead candidate, NV-387, into Phase II clinical trials for the treatment of MPox infection. This decision follows substantial efficacy data in animal studies for multiple indications, including RSV, Influenza, COVID, and Orthopoxviruses. The company has engaged a Clinical Research Organization to conduct the trial, with a site established in the Democratic Republic of Congo. The Clinical Trial Application is nearing completion, and manufacturing of the NV-387 substance is largely finished. The trial aims to expedite the company's pipeline towards revenue generation, with plans to extend NV-387's application to respiratory infections following the MPox trial. Results from this clinical study have yet to be presented.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。